Activist Capital Boosts Diabetes Patch Stock, Market Cap Soars by 2.8 Trillion Won in One Day

Dexcom Inc., a U.S.-based maker of continuous glucose monitoring (CGM) devices, closed trading on the Nasdaq at $71.50 on the 20th, marking a 6.8% jump. Volume topped about 8.9 million shares, far above its average, while market capitalization climbed by roughly $2 billion (approximately KRW 2.8 trillion) to reach about $27.6 billion (KRW 38.6 trillion).

Dexcom’s stock has rebounded recently on the back of activist investor Elliott Management’s stake acquisition, board seats, and the prospect of strategic guidance. This momentum was reinforced by first-quarter results that outperformed market expectations, the launch of its new G8 continuous glucose monitoring system, and renewed “buy” recommendations from leading brokerage firms, all of which have restored confidence in its growth story.

As a specialized medical-device company, Dexcom develops, manufactures, and sells CGM systems for diabetes patients, holding a leading position in the global CGM market alongside Abbott and Medtronic. With its G7 15-day sensor and upcoming next-generation G8 platform, the company is targeting over $5 billion in revenue by 2026, and aims to sustain growth by expanding into the non-insulin-treated type 2 diabetes segment.